◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Narayana Hrudayalaya Limited (NH) Revenue 2023–TTM

Name: Narayana Hrudayalaya Limited (NH) revenue history 2023-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-10-22

Narayana Hrudayalaya Limited annual revenue for fiscal TTM was ₹90.7 billion, an increase of 15.5% from ₹78.6 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

NH Annual Revenue

Revenue (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹90.7B	₹78.6B	₹54.6B	₹48.8B	₹44.9B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NH Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹26.8B	₹25.9B	₹21.5B	₹16.4B	₹15.1B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

MANIPALHOS Revenue — Manipal Health Enterprises Limited
MAXHEALTH Revenue — Max Healthcare Institute Limited
ASTERDM Revenue — Aster DM Quality Care Limited
FORTIS Revenue — Fortis Healthcare Limited
MEDANTA Revenue — Global Health Limited
BDMS Revenue — Bangkok Dusit Medical Services Public Company Limited

More NH metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All NH financial statements → Interactive NH charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.